Your browser doesn't support javascript.
[The use of neurotropic therapy in young patients with postcovid syndrome]. / Primenenie neirotropnoi terapii u molodykh patsientov s postkovidnym sindromom.
Ivonina, N A; Petrov, K B.
  • Ivonina NA; Novokuznetsk State Institute for Advanced Medical Studies, Novokuznetsk, Russia.
  • Petrov KB; Novokuznetsk State Institute for Advanced Medical Studies, Novokuznetsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova ; 122(3): 126-130, 2022.
Article in Russian | MEDLINE | ID: covidwho-1786403
ABSTRACT

OBJECTIVE:

The aim of the present study was to identify postcovid asthenic syndrome and cognitive disorders in young patients on an outpatient basis, and to evaluate the experience of using combined neurotropic therapy in this category of patients. MATERIAL AND

METHODS:

Included 87 young patients who underwent COVID-19 and applied for an outpatient appointment with a neurologist. All patients underwent a scale assessment of the severity of asthenia on the MFI-20 scale, cognitive functions - on the MMSE scale, the 5-word test and the Schulte test. The severity of the anxiety syndrome - according to the Spielberger Anxiety Scale. All patients in the study group were treated with a combination of Cortexin and Recognan, and a repeat study was conducted 4 weeks after treatment.

RESULTS:

The study revealed the predominance in the observation group of patients with a comorbid background, as well as pronounced anxiety disorders. After the complex treatment, there was a significant decrease in the indicators of common, physical, mental asthenia, as well as an increase in motivational activity, there was a decrease in situational anxiety, and to a lesser extent personal anxiety. According to cognitive tests, there was an improvement in indicators on the MMSE scale, direct reproduction of the 5-word test, significant changes in the evaluation of work efficiency when performing the Schulte test.

CONCLUSION:

It should be noted that the positive results of this study can be considered a decrease in the severity and severity of asthenia symptoms, a decrease in anxiety manifestations, and an improvement in cognitive functions against the background of complex neurotropic therapy with Cortexin and Recognan. Preference in this situation should be given to drugs with a multimodal mechanism of action, as well as creating optimal combinations of drugs that potentiate each other's action.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cognition Disorders / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: Russian Journal: Zh Nevrol Psikhiatr Im S S Korsakova Journal subject: Neurology / Psychiatry Year: 2022 Document Type: Article Affiliation country: Jnevro2022122031126

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cognition Disorders / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Topics: Long Covid Limits: Humans Language: Russian Journal: Zh Nevrol Psikhiatr Im S S Korsakova Journal subject: Neurology / Psychiatry Year: 2022 Document Type: Article Affiliation country: Jnevro2022122031126